N/A N=15 Autoimmune Protocol Diet and Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Number of Participants With Clinical Remission for Crohn's Disease — 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
N/A N=95,055 Healthcare Resource Utilisation, Common Mental Health Problems, and Infections in People With Inflammatory Bowel Disease
Inflammatory Bowel Diseases · Ulcerative Colitis · Crohn Disease
Primary: Prevalence of Anxiety Episodes (Crohn's Disease) — 262; 892 Participants
N/A N=53 Stress in Inflammatory Bowel Disease
Inflammatory Bowel Diseases · Psychological
Primary: Retention Rate — 23; 25; 19; 22 Participants
N/A N=50 Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease
Inflammatory Bowel Disease · Glycogen Storage Disease Type Ia
Primary: Serologic, Genetic and Inflammatory Markers Consistent With Inflammatory Bowel Disease — 11 participants testing positive
Phase 1 N=13 Bacteriotherapy in Pediatric Inflammatory Bowel Disease
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Number of Participants Who Responded to Stool Translplantation By 2 Weeks as Determined by Pediatric Ulcerative Colitis Activity Index (PUCAI)/Pediatric Crohn's Disease…
N/A N=326 A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)
Inflammatory Bowel Diseases · Colitis, Ulcerative · Crohn Disease
Primary: Percentage of Participants With Active CD at Day 1 — 45.3 percentage of participants
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 2 N=34 Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care
Inflammatory Bowel Disease · Ulcerative Colitis · Crohn's Disease
Primary: Patient Clinical Experience — 1.2; 1.3 units on a scale — p=<0.05
N/A N=19,469 Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
Inflammatory Bowel Diseases · Depressive Episode · Recurrent Depressive Disorder
Primary: Stream 1: Percentage of Participants Who Developed Any Mental Health Condition — 12.0; 9.4 percentage of participants
N/A N=407 Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil
Inflammatory Bowel Disease
Primary: Percentage of Participants With Active Crohn's Disease (CD) at Day 1 — 16.52; 25.97 percentage of participants
N/A N=1,901 A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice
Colitis, Ulcerative · Crohn Disease · Inflammatory Bowel Diseases
Primary: Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD…
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Phase 1 N=20 Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
Inflammatory Bowel Disease (IBD)
Primary: Clinical Response — 9 Participants — p=0.03
N/A N=33 A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease
Inflammatory Bowel Disease
Primary: Exploratory: Levels of IL-6/sIL-6R Complex — NA pg/mL
Phase 4 N=81 Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
Inflammatory Bowel Disease (IBD)
Primary: Measure Antibody Concentrations in Immunosuppressed IBD Patients Who Receive High Dose and Standard of Care Dose Influenza Vaccine — 160; 160; 160; 160 Antibody Titer
N/A N=33 Imaging Biomarkers in Crohn's Associated Spondyloarthritis
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
N/A N=45 Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)
Inflammatory Bowel Diseases
Primary: Pre-treatment Serum Level of Endogenous Anti-TNF in Relation to Primary Clinical Response or Non-response — NA endogenous anti-TNF serum level (µg/mL)
Phase 3 N=348 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
Inflammatory Bowel Disease · Crohn's Disease · Ulcerative Colitis
Primary: Harvey Bradshaw Index — 3.7; 3.2; 4.2 units on a scale
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
N/A N=45 Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children
IBD
Primary: Diagnostic Yield of Magnetic Resonance Enterography (MRE) — 52 % Percentage of Diagnostic yeild
N/A N=115 Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Average Dose of Inflectra at Visit 1 — 457.28; 585.71; 579.44; 449.76 milligram
N/A N=310 A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease
Inflammatory Bowel Disease
Primary: Impact of the Comorbidities Profile in Inflammatory Bowel Disease (IBD) Participants on Lack of Treatment Response to Biological Therapy — 0.59; 2.16; 2.67 odds ratio…
N/A N=30 Digital Behavioral Interventions in Inflammatory Bowel Disease
Crohn Disease · Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Level of Psychological Distress — 60.8; 59.4 T-score
N/A N=9,573 Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
Colitis, Ulcerative · Inflammatory Bowel Diseases · Crohn's Disease
Primary: Mortality Rate — 21.4; 30.1 events per 1000 person-years
N/A N=15 The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm
N/A N=79 Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
Crohn's Disease · Ulcerative Colitis · Healthy Controls
Primary: Levels of TNF (Tumor Necrosis Factor Alpha) and TNF-dependent Chemokines (MCP1, MIP-1beta and IP10) in Breast Milk of Women With IBD and Healthy Controls by Multiplex…
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
Phase 2 N=7 Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
Irritable Bowel Syndrome
Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001
Phase 2 N=22 Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis
Ulcerative Colitis
Primary: Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1…